Numinus Now Offers Ketamine-Assisted Therapy in Toronto Post published:September 19, 2022 Post category:Press Release
Numinus provides update on acquisition integration and announces new client financing options Post published:September 13, 2022 Post category:Press Release
Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022 Post published:August 31, 2022 Post category:Press Release
Numinus Wellness Inc. Reports Q3 2022 Results Post published:July 16, 2022 Post category:Press Release
Numinus to Host Q3 2022 Results Conference Call on July 14, 2022 Post published:July 7, 2022 Post category:Press Release
Numinus Applies for International Patent Filing of Psychedelics Production Process Post published:June 22, 2022 Post category:Press Release
Numinus Wellness Inc. Reports Q2 2022 Results Post published:April 14, 2022 Post category:Press Release
Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research Post published:April 12, 2022 Post category:Press Release
Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS Post published:March 30, 2022 Post category:Press Release